CYCLO THERAPEUTICS INC (CYTH)

Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q1 2024

Cyclo Therapeutics just reported results for the first quarter of 2024.

CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclo Therapeutics (NASDAQ:CYTH) just reported results for the fourth quarter o...

CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023

Cyclo Therapeutics just reported results for the fourth quarter of 2023.

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq –

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPLK, CYTH, AMTI, EBC

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq – NXGN), Computer Task Group, Incorporated (Nasdaq -

CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders

Applied Molecular stock falls on merger with Cyclo Therapeutics

Applied Molecular Transport (AMTI) and Cyclo Therapeutics (CYTH) announced a merger agreement on Thursday whereby Applied Molecular (AMTI). Read more here.

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results